HC Wainwright Issues Pessimistic Outlook for IPA Earnings

Key Points

• HC Wainwright has lowered its Q1 2026 earnings estimate for ImmunoPrecise Antibodies to ($0.04) per share, down from a prior estimate of ($0.03), while maintaining a "Buy" rating and a target price of $5.00.
• ImmunoPrecise reported Q1 earnings of ($0.04) per share, missing analysts' expectations of ($0.02) and generating $5.06 million in revenue, below the consensus estimate of $7.89 million.
• Wall Street Zen has updated its rating for ImmunoPrecise Antibodies to "sell," reflecting concerns about the company's financial performance and outlook.

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA - Free Report) - Research analysts at HC Wainwright dropped their Q1 2026 earnings estimates for shares of ImmunoPrecise Antibodies in a research report issued on Wednesday, July 30th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of ($0.04) per share for the quarter, down from their previous estimate of ($0.03). HC Wainwright currently has a "Buy" rating and a $5.00 target price on the stock. The consensus estimate for ImmunoPrecise Antibodies' current full-year earnings is ($0.27) per share. HC Wainwright also issued estimates for ImmunoPrecise Antibodies' Q2 2026 earnings at ($0.01) EPS, Q3 2026 earnings at $0.00 EPS, Q4 2026 earnings at $0.01 EPS, FY2026 earnings at ($0.04) EPS, FY2027 earnings at $0.04 EPS and FY2030 earnings at $0.25 EPS.

Separately, Wall Street Zen raised shares of ImmunoPrecise Antibodies from a "sell" rating to a "hold" rating in a research note on Saturday.

ImmunoPrecise Antibodies Stock Performance

Shares of NASDAQ:IPA traded down $0.05 during trading on Friday, reaching $1.79. 493,504 shares of the company's stock traded hands, compared to its average volume of 4,301,793. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.08 and a quick ratio of 1.85. The company has a 50 day moving average of $1.25 and a 200-day moving average of $0.72. The stock has a market capitalization of $82.38 million, a P/E ratio of -2.62 and a beta of 0.49. ImmunoPrecise Antibodies has a 12 month low of $0.27 and a 12 month high of $2.41.

ImmunoPrecise Antibodies (NASDAQ:IPA - Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The company reported ($0.04) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.02). ImmunoPrecise Antibodies had a negative net margin of 122.10% and a negative return on equity of 40.62%. The business had revenue of $5.06 million for the quarter, compared to the consensus estimate of $7.89 million.

Institutional Trading of ImmunoPrecise Antibodies

An institutional investor recently raised its position in ImmunoPrecise Antibodies stock. Ingalls & Snyder LLC increased its position in shares of ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA - Free Report) by 0.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,779,363 shares of the company's stock after acquiring an additional 21,236 shares during the quarter. Ingalls & Snyder LLC owned 6.07% of ImmunoPrecise Antibodies worth $2,946,000 as of its most recent SEC filing. 6.70% of the stock is currently owned by institutional investors.

ImmunoPrecise Antibodies Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.